Orkambi 75 mg/94 mg granules in sachet
Authorisation EU/1/15/1059/008 · Vertex Pharmaceuticals (Ireland) Limited
- Licence holder
- Vertex Pharmaceuticals (Ireland) Limited (all products →)
- Active substances
- Lumacaftor, Ivacaftor
- Clinical trials
- 5 clinical trials →
- Dosage form
- Granules
- Route of administration
- Oral use
- ATC code
- R07AX30
- First authorised
- 19/11/2015
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Known active substance (Article 8(3) of Directive No 2001/83/EC)
Lumacaftor: supply and approvals
5 authorised products on the HPRA list contain Lumacaftor. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
Ivacaftor: supply and approvals
19 authorised products on the HPRA list contain Ivacaftor. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1059. It has been authorised for 11 years (since 19 November 2015). The HPRA list does not say whether it is on sale.
Other medicines with Lumacaftor in Ireland
4 other products on the HPRA list contain Lumacaftor, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Orkambi 100 mg/125 mg film-coated tablets | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Orkambi 100 mg/125 mg granules in sachet | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Orkambi 150 mg/188 mg granules in sachet | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Orkambi 200 mg/125 mg film-coated tablets | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
Other medicines with Ivacaftor in Ireland
18 other products on the HPRA list contain Ivacaftor, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Ivacaftor Teva 150 mg film-coated tablets | TEVA GmbH | National authorisation (PA) | Not marketed |
| Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kaftrio 60 mg/40 mg/80 mg granules in sachet | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kaftrio 75 mg/50 mg/100 mg film-coated tablets | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kaftrio 75 mg/50 mg/100 mg granules in sachet | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kalydeco 13.4 mg granules in sachet | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kalydeco 150 mg film-coated tablets | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kalydeco 150 mg film-coated tablets | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kalydeco 50 mg granules in sachet | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kalydeco 59.5 mg granules in sachet | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kalydeco 75 mg film-coated tablets | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
| Kalydeco 75 mg granules in sachet | Vertex Pharmaceuticals (Ireland) Limited | Centralised EU authorisation | Not stated |
The licence holder
Vertex Pharmaceuticals (Ireland) Limited holds 21 products on the HPRA list, with 8 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.